Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchPredicine, Inc. announces the clinical utility of PredicineCARE™ liquid biopsy assay as featured in NEJM for patient enrollment in Phase III Breast Cancer Trial.
Predicine, Inc. has published a landmark study in NEJM demonstrating the clinical utility of its PredicineCARE™ liquid biopsy assay for identifying and enrolling PIK3CA-positive breast cancer patients in a Phase III trial.
Company Information
Company
Predicine
Location
Hayward, California, United States
About
Predicine is a global molecular insights company committed to advancing precision medicine in oncology and infectious disease diagnostics. It develops proprietary technologies for cell-free DNA and cell-free RNA liquid biopsy for minimally invasive molecular diagnoses. Predicine's portfolio includes blood, urine, and tissue-based NGS assays designed for clinical trial and companion diagnostic development. The company collaborates with leading biopharma companies and institutions to support personalized healthcare globally.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Predicine ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.